Latest research on Harvoni

Sofosbuvir is a medication used as part of combination therapy to treat hepatitis C virus (HCV) infection or HCV and HIV co-infection. Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B polymerase. Sofosbuvir was approved by the FDA in December 2013, and is marketed under the brand name Sovaldi.

Harvoni dosage

Harvoni (sofosbuvir+ledipasvir; GS7977+GS-5855) is a fixed-dose combination tablet containing ledipasvir (90 mg) and sofosbusvir (400 mg) for oral administration. [source, 2016]